Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

How much is biktarvy a month?

See the DrugPatentWatch profile for biktarvy

Price for Biktarvy can vary a lot by country, pharmacy, and your insurance or patient-assistance options. In the United States, a 30-tablet supply (one month) is typically listed at several thousand dollars before insurance, but what you actually pay can be much less or even $0 with coverage or assistance programs. Many people pay hundreds of dollars per month or less depending on their plan.

A few ways to get an exact number right now:
- Check your local pharmacy for the cash price (some pharmacies show a price online).
- Use a price comparison tool (e.g., GoodRx) to see current cash prices at nearby pharmacies.
- Check what your insurance would pay (formulary status, copay, deductible).
- See if you qualify for manufacturer or patient-assistance programs (Gilead’s Advancing Access, etc.).

If you tell me:
- your country,
- whether you have insurance and what type (private, government, Medicare/Medicaid),
- and if you want, your current quote from a specific pharmacy,
I can help estimate your likely monthly out-of-pocket and point you to relevant programs.



Other Questions About Biktarvy :

Biktarvy launch date? Why is biktarvy so expensive? When does biktarvy lose patent protection? Biktarvy generico? Generic biktarvy? Biktarvy vs dovato? Biktarvy precio farmacia del ahorro?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The provided content is consistent with the label excerpts for BIKTARVY regarding HBV testing, risk of severe acute hepatitis B exacerbation after discontinuation, and patient counseling not to discontinue without provider input.


Category Scores

Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent

Accurate Statements

Patients with HIV-1 should be tested for the presence of chronic HBV before or when initiating antiretroviral therapy.
5.1 and 2.1 (HBV testing prior to or when initiating BIKTARVY)
Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing FTC and/or TDF, and may occur with discontinuation of BIKTARVY.
5.1
Patients with HIV-1 and HBV who discontinue BIKTARVY should be closely monitored with clinical and laboratory follow-up for at least several months after stopping treatment.
5.1
If appropriate, anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis.
5.1
Severe acute exacerbations of hepatitis B have been reported in patients with HBV and HIV-1 who have discontinued products containing FTC and/or TDF, and may occur with discontinuation of BIKTARVY.
17 (Patient Counseling Information)
Advise the patient not to discontinue BIKTARVY without first informing their healthcare provider.
17

Unsupported Statements


Contradictions


Important Omissions

No full labeling evaluation was possible beyond the provided excerpts because no additional AI response claims were supplied for assessment (e.g., dosage specifics, contraindications, boxed warnings, drug interactions, adverse reactions, storage/handling).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The evaluated statements align with label warnings/precautions and patient counseling regarding HBV testing and post-discontinuation HBV exacerbation monitoring.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement